Myriad myPlan® Lung Cancer measures how fast a lung cancer tumor is growing. Fast growing tumors are more aggressive and correlated with higher risk. Tissue samples collected during surgery are used to determine the mPS and calculate the patient’s five-year survival probability. Several studies have shown that myPlan Lung Cancer is an accurate and reproducible risk assessment test that is based on the biological nature of the patient’s tumor. 1,2,3

Personalizing Risk Assessment and Treatment Decisions in Lung Cancer

No two cancers are the same, and it can be difficult to predict which tumors are slow-growing and which are likely to grow and spread to other parts of the body.

Current medical society guidelines rely on cancer stage to determine lung cancer treatment, including early-stage non-small cell lung adenocarcinoma. Classification of lung cancer stage is based primarily on the size and location of the tumor and serves as an indicator of disease progression.

However, cancer stage alone does not reveal the aggressiveness of the tumor. In fact, two patients with the same lung cancer stage may have very different estimates of mortality risk when tumor aggressiveness is taken into account.1,2,3

The Myriad myPlan Lung Cancer prognostic score combines molecular information with cancer stage to better predict the five-year risk of lung cancer-specific death than stage alone. Gaining insight into tumor aggressiveness will also help determine if surgery alone is sufficient, or if more aggressive treatment is needed.*

Learn more about Myriad myPlan Lung Cancer


*Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

References

1. Bueno R, et al. Validation of a molecular and pathological model for fiver-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 2015; 10:67-73.

2. Rakha E, et al. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. Eur J Cancer 2015; 51:1897-1903

3. Eguchi E, et al. Validation of a cell cycle progression score for five-year mortality risk in patients with stage I lung adenocarcinoma. Presented at ASCO 2015.

3. Wistuba II, Behrens C, Lombardi F, et al. Prognostic Marker in Early Stage Lung Adenocarcinoma. Clinical Cancer Research. November 15, 2013 19:6261-6271